Gainers Quantum-Si (NASDAQ:QSI) stock rose 30.3% to $1.59 during Friday's regular session. The

Cue Biopharma NASDAQ: CUE reported positive top-line results from a Phase II trial of CUE-221 in pat

Cue Biopharma (NASDAQ: CUE) reported positive top-line results from a Phase II trial of CUE-221 in p

I am initiating Cue Biopharma with a "Buy" rating, driven by positive phase 2 results for CUE-221 in

Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular sessio

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Sponta

Cue Biopharma (NASDAQ:CUE) on Sunday shared topline results from a Phase 2 trial of CUE-221 in patie

Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and fa

Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market ses

Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several sma

Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-

Results support potential for differentiated clinical impact for patients suffering from chronic hiv

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy rati

B. Riley Securities analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ:CUE) with

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating C

Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's aft

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopha

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformati

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopha

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in

Gainers VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-m

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopha

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launche

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therape

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(1.08) per share which missed the analyst c

Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expe

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on

AAPL: 4% | Apple shares are trading higher after the company reported better-than-expected Q2 financ

Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,

Cue Biopharma Inc. shares surged 67.57% after announcing a $30M financing, anti-IgE antibody license

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel clas

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph

Cue Biopharma, Inc. (NASDAQ:CUE) shares are tumbling on Wednesday after the company announced a reve

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph

Bloom Energy (BE) rose in pre-market trading as it announces expanded partnership with Oracle (ORCL)